| September 1997 |
Established Pharma Foods Research Co., Ltd., a functional food ingredient development and sales company in Kyoto prefecture with a capital of 10 million Japanese yen |
| May 2001 |
Introduction of Ovopron, a Helicobacter Pylori antibody in the market |
| September 2001 |
Introduction of PharmaGABA, a GABA-containing ingredient in the market |
| October 2003 |
Introduction of Delicious Catechin, a catechin ingredient |
| October 2004 |
Changed the company name to Pharma Foods International Co., Ltd. |
| May 2006 |
Established KEIHANNA Research center for Bio Medical development |
| May 2006 |
Introduction of Bonepep, an egg yolk peptide ingredient |
| June 2006 |
Went public and listed in Mothers, a Tokyo Stock Exchange market |
| September 2006 |
Moved the head office to the west ward of Kyoto (to the current location) |
| October 2006 |
Introduction of Runpep, an egg white peptide ingredient |
| April 2007 |
Established Hiroshima Bio Medical company in Hiroshima (49% PFI shares) |
| February 2010 |
Created LSI Department to launch CRO business |
| September 2010 |
Launched Enriched Folic Acid eggs business in China |
| February 2012 |
Started B to C business |
| July 2012 |
Established Dongbu Farm PFI. Co., Ltd. in partnership with Dongbu group in Korea (49% PFI shares) |
| July 2012 |
Introduction of iHA, hyaluronic acid production stimulating ingredient |
| August 2012 |
Launched ‘Tamagokichi’, a B to C direct sales brand and introduced a new joint health supplement ‘Tamagosamine with iHA’ |
| October 2012 |
Acquired additional shares of Benart Co., Ltd. (50% PFI shares) |
| September 2013 |
Started sale of electricity produced by Benart Co., Ltd. |
| September 2013 |
Acquired Hiroshima Bio Medical company |
| September 2014 |
Opened the Company’s own call center for the Tamagokichi® e-commerce sales brand |
| May 2015 |
Acquired the ISO 9001 quality management system certification |
| August 2015 |
Established PharmaFoods Communication Inc. to conduct call center operations for health foods and cosmetics (made a wholly
owned subsidiary in December 2018, currently a consolidated subsidiary) |
| December 2015 |
Began joint research with the National Cancer Center Japan to develop antibodies to treat malignant tumors |
| November 2016 |
To expand the Bio Value business, made FUTURE LABO Inc. a subsidiary (currently a consolidated subsidiary) |
| December 2016 |
Listing was changed to the TSE Second Section |
| October 2018 |
Concluded a joint research agreement with Mitsubishi Tanabe Pharma Corporation for antibody pharmaceuticals indicated for the
treatment of autoimmune diseases |
| November 2018 |
Market launched Newmo® Hair Growth Formula, a non-pharmaceutical product formulated with HGP® |
| February 2021 |
Listing was upgraded to the TSE First Section |
| August 2021 |
Invested in Ai-BrainScience Inc., which is developing a cognitive function diagnostic app
Made a wholly owned subsidiary of Meiji Yakuhin Co., Ltd., which manufactures and sells pharmaceuticals and nonpharmaceutical
products |